Literature DB >> 19961259

Adult orbital xanthogranulomatous disease: review of the literature.

Jin Guo1, Jun Wang.   

Abstract

This article provides an overview of the pathologic features of adult orbital xanthogranulomatous disease, a rare heterogeneous group of disorders that includes 4 clinical syndromes: adult-onset xanthogranuloma, necrobiotic xanthogranuloma, adult-onset asthma and periocular xanthogranuloma, and Erdheim-Chester disease. The diagnosis is made by biopsy of the lesion, demonstrating tissue infiltration by the hallmarks of xanthoma cells and Touton giant cells. The differential diagnosis is broad, including syndromes within the adult xanthogranulomatous disease category as well as other entities involving the eyelid and the orbital tissues. Because of its rarity and sometimes close similarity to other disease entities, it is often misdiagnosed initially. This article focuses on the morphology and immunohistochemical patterns in diagnosis of adult orbital xanthogranulomatous disease with emphasis on adult-onset asthma and periocular xanthogranuloma in particular, its clinical features and associated systemic manifestations in differential diagnosis, as well as the current management strategy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19961259     DOI: 10.5858/133.12.1994

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  16 in total

Review 1.  [Erdheim-Chester disease and Rosai-Dorfman disease: Pathological, radiological and clinical features of adult non-Langerhans cell histiocytosis].

Authors:  H Bösmüller; D Nann; M Horger; F Fend
Journal:  Pathologe       Date:  2015-09       Impact factor: 1.011

2.  MRI Findings of Adult-Onset Orbital Xanthogranulomatous Disease : A Case Report.

Authors:  Joo Kyung Sim; Ji Ye Lee; Sun Young Jang; Susie Chin
Journal:  Clin Neuroradiol       Date:  2018-02-09       Impact factor: 3.649

3.  Unusual presentation of adult xanthogranuloma: a case report.

Authors:  Lixian Chris Tan; Kong Bing Tan; Chen Wee Derrick Aw
Journal:  Singapore Med J       Date:  2014-02       Impact factor: 1.858

Review 4.  Successful treatment with rituximab of IgG4-related disease coexisting with adult-onset asthma and periocular xanthogranuloma.

Authors:  Ioannis Asproudis; Maria Kanari; Ioannis Ntountas; Vasileios Ragos; Anna Goussia; Anna Batistatou; Paraskevi Vasileios Voulgari
Journal:  Rheumatol Int       Date:  2019-08-07       Impact factor: 2.631

5.  Bilateral extensive nodular xanthelasma palpebrarum: an infrequent case report.

Authors:  Pei Wang; Qingli Luo; Li Tang
Journal:  Int Ophthalmol       Date:  2017-04-03       Impact factor: 2.031

6.  Symmetrical Periorbital Yellow Plaques in a Patient with Haematological Dyscrasia: A Quiz.

Authors:  Emanuele Cozzani; Andrea Muracchioli; Giulio Fraternali Orcioni; Aurora Parodi
Journal:  Acta Derm Venereol       Date:  2021-12-07       Impact factor: 3.875

7.  The epidemiology, clinical characteristics, histopathology and management of juvenile- and adult-onset corneoscleral limbus xanthogranuloma.

Authors:  G Kontos; S Borooah; A Khan; B W Fleck; S E Coupland
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-21       Impact factor: 3.117

8.  Update in pathological diagnosis of orbital infections and inflammations.

Authors:  Vincent B Lam Choi; Hunter K L Yuen; Jyotirmay Biswas; Myron Yanoff
Journal:  Middle East Afr J Ophthalmol       Date:  2011-10

9.  Limbal xanthogranuloma in a dog.

Authors:  Juri Ota-Kuroki; Keiichi Kuroki
Journal:  J Vet Med Sci       Date:  2017-06-15       Impact factor: 1.267

10.  Adult Onset Asthma and Periocular Xanthogranuloma (AAPOX), a Rare Entity With a Strong Link to IgG4-Related Disease: An Observational Case Report Study.

Authors:  Jonathan London; Antoine Martin; Michael Soussan; Isabelle Badelon; Thomas Gille; Yurdagul Uzunhan; Bénédicte Giroux-Leprieur; Ursula Warzocha; Alexis Régent; Olivier Galatoire; Robin Dhote; Sébastien Abad
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.